ADA: Inhaled Insulin Shows Promise for Adults With Type 1 Diabetes
By Lori Solomon HealthDay Reporter
THURSDAY, June 27, 2024 -- Inhaled insulin is associated with improved hemoglobin A1c (HbA1c) levels over 16 weeks among adults with type 1 diabetes when compared to usual care, according to a study presented at the annual meeting of the American Diabetes Association, held from June 21 to 24 in Orlando, Florida.
Irl B. Hirsch, M.D., from the University of Washington in Seattle, and colleagues conducted a randomized trial that compared the efficacy of an inhaled insulin regimen (Afrezza) plus degludec insulin (Tresiba) to usual care for 17 weeks among adults with type 1 diabetes treated at 19 U.S. centers.
The researchers found that more participants using the inhaled insulin regimen experienced significant improvements in HbA1c levels versus usual care, including 21 percent of those on inhaled insulin with HbA1c improvement >0.5 percent versus 5 percent for those receiving standard care. Among participants with HbA1c level ≥7 percent at baseline, 21 percent of those on inhaled insulin achieved the HbA1c goal of <7 percent, while no participants receiving standard care achieved the goal. Among participants who switched from using an automated insulin delivery system to using inhaled insulin plus degludec, 19 percent achieved an HbA1c improvement >0.5 percent. However, 26 percent of the patients in the inhaled insulin group had a worsening of HbA1c >0.5 percent versus 3 percent receiving standard care.
"The INHALE-3 study’s findings will impact diabetes management by providing healthcare providers and patients with an alternative insulin delivery method," Hirsch said in a statement. "These results will assist in better informing clinical decisions and tailoring treatment plans to individual patient needs, potentially improving adherence, patient satisfaction, and overall outcomes."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted June 2024
Read this next
Risk for Death, MACE Increased for Patients With Adult-Onset Type 1 Diabetes
FRIDAY, May 16, 2025 -- Adult-onset type 1 diabetes (T1D) is associated with an increased risk for death and major adverse cardiovascular events (MACE), according to a study...
Rise in Prevalence of Obesity in Youth, Adults With T1DM Seen From 2008 to 2023
FRIDAY, April 4, 2025 -- From 2008-2011 to 2020-2023, there was an increase in the prevalence of obesity among youth and adults with type 1 diabetes, and glucagon-like peptide 1...
Low-Glucose Alerts Beneficial for Insulin-Treated Drivers With Diabetes
FRIDAY, March 21, 2025 -- For individuals with type 1 diabetes, low-glucose alerts improve the time below range for drivers and reduce the incidence of low glucose while driving...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.